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Abstract
Objectives. The aim was to characterize disease severity, clinical manifestations, treatment patterns
and flares in a longitudinal cohort of adults with SLE in the UK.
Methods. Adults with SLE were identified in the Clinical Practice Research Datalink–Hospital Episode
Statistics database (1 January 2005–31 December 2017). Patients were required to have 12 months
of data before and after the index date (earliest SLE diagnosis date available). SLE disease severity
and flares were classified using adapted claims-based algorithms, which are based on SLE-related
conditions, medications and health-service use.
Results. Of 802 patients, 369 had mild, 345 moderate and 88 severe SLE at baseline. A total of 692
initiated treatment in the first year after diagnosis. Five hundred and fifty-seven received antimalarials,
203 immunosuppressants and 416 oral CSs. Information on biologic use in hospitals was unavailable.
The mean (S.D.) time to initiating any medication was 177 (385.3) days. The median time to first flare
was 63 days (95% CI: 57, 71). At least one flare was experienced by 750 of 802 patients during
follow-up; the first flare was mild for 549 of 750, moderate for 116 of 750 and severe for 85 of 750.
The mean (S.D.) annual overall flare rate (year 1) was 3.5 (2.5). A shorter median time to first flare was
significantly associated with moderate/severe disease (P< 0.001) and clinical manifestations (P< 0.001).
Conclusion. Our findings suggest some delay in the initiation of SLE treatment. Most patients experi-
ence a flare within 2 months of diagnosis. Early treatment might delay or reduce the severity of the first
SLE flare and might translate to slower disease progression, lower accrual of organ damage and better
outcomes.
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Key messages
. This is a longitudinal study to describe disease severity and activity in UK SLE patients over 6 years.
. SLE patients, on average, initiate treatment 6 months after diagnosis.
. There may be opportunities to change SLE management and improve patient outcomes.
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SLE is a systemic autoimmune disease characterized by
autoantibody presence and immune complex deposition
in affected tissues [1]. SLE can involve multiple organ sys-
tems, resulting in diverse clinical manifestations that range
from fatigue and mild skin rash to end-stage renal failure
[2]. Patients with SLE are at increased risk of developing
comorbid conditions, including those involving the renal,
cerebrovascular, hepatic, gastrointestinal and neurological
organ systems [3–5]. All-cause mortality in SLE is >3-fold
compared with the general population [6, 7].
The clinical course of SLE is marked by periods of
remission, which may be spontaneous or induced by
treatment, interspersed by periods of increased disease
activity known as SLE flares [8]. SLE flare episodes usu-
ally require consideration for changes in treatment or
increased medication doses of existing treatment [9].
Flares have been associated with an increased risk of
organ damage [10], and 50% of all patients with SLE
experience some form of organ damage within 10 years
of diagnosis [11]. The use of oral CSs for SLE treatment
and management of flares is associated with side
effects, including the risk of contributing to chronic
organ damage and infection. Recent SLE treatment
guidelines recommend the lowest possible oral CS doses
followed by taper or discontinuation when decreased
flare frequency and severity is achieved, and other
immunosuppressive agents show benefit [2, 12].
There are limited longitudinal data describing real-world
SLE disease characteristics and flares in the UK. Our
study aimed to characterize disease severity, clinical mani-
festations, treatment patterns and flares in a longitudinal
cohort of patients with new-onset SLE in the UK.
Methods
Study design
We conducted an observational, retrospective cohort
study of adult patients with new-onset SLE in the UK
identified in the Clinical Practice Research Datalink
(CPRD) and Hospital Episode Statistics (HES)–linked
health-care administrative databases and Office for
National Statistics mortality files from 1 January 2005 to
31 December 2017. Patients were required to have
12 months of SLE disease-free time before the index
date (date of first SLE diagnosis) and 12 months of
follow-up (up to 31 December 2017) (Fig. 1A). Approval
for this study was granted by the Independent Scientific
Advisory Committee for Medicines and Healthcare
products Regulatory Agency on 8 March 2018
(CPRD00023132 PROTOCOL 17_281R).
Data sources
Data were sourced from three routinely obtained and
linked data sources in the UK. The CPRD database
used in this study was CPRD GOLD, contributed to by
general practices using VISION software and collected
since 1987. CPRD GOLD contains anonymous longitudi-
nal medical records of >14 million patients, is broadly
representative of the UK population in terms of age and
sex, and has information on demographics, diagnoses
and primary health-care utilization, including outpatient
prescription medications [13, 14], and has been shown
in a number of validation studies to be generally of high
quality [15, 16]. The CPRD primary care database has
been used previously to describe the epidemiology of
SLE in the UK [17–28].
These primary care data were linked to secondary
care information [hospital admissions, and the
International Classification of Diseases, Tenth Revision
(ICD-10) for the coding of diagnosis and type of admis-
sion] identified in the HES database. Death registration
data, to identify mortality and causes of death, were
obtained from the Office for National Statistics. CPRD
GOLD linkage data include patients from 416 practices,
covering 50% of contributing CPRD GOLD practices in
the UK. All data were anonymized, and linkage, by pa-
tient identifiers held by CPRD, was conducted by
CPRD.
Population
All patients presenting to a general practitioner or hospi-
tal, aged 18 years and with at least one diagnosis of
SLE during the study period were eligible for inclusion in
the study. For CPRD GOLD, SLE diagnosis was
recorded using a Read code, a standard clinical
terminology system used in general practice in the UK,
indicating a clinical test or referral event. For the HES
database, SLE diagnosis was recorded using ICD-10
codes. Code lists were determined by a panel of clinical
experts and aligned with published lists of SLE Read
codes from previous CPRD studies [25] (Supplementary
Table S1, available at Rheumatology Advances in
Practice online). A diagnosis of SLE was confirmed with
repeat diagnosis of SLE (in CPRD or HES) or a rheuma-
tologist appointment/referral and/or through SLE medi-
cation (Supplementary Table S2, available at
Rheumatology Advances in Practice online) [22].
Patients were excluded if they had Read codes indicat-
ing cutaneous, drug-induced or discoid lupus rather
than systemic lupus; they did not have a definite code
anywhere in their CPRD record or in HES to confirm
diagnosis; they transferred out of the practice before the
index event date (date of first eligible diagnosis); or they
did not have 12 months of valid data before the index
diagnosis. Only new-onset (i.e. incident) cases, defined
by 12 months of prior diagnosis-free period, were
included in this analysis.
Classification of SLE disease and flare severity
Components of SLE disease measures are not captured
comprehensively and routinely in real-world databases,
administrative and claims data [22, 29]. SLE disease
severity was classified using an algorithm that combines
SLE diagnosis, SLE-related conditions (based on a
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FIG. 1 Time line of study (A) and flowchart of study cohort (B)




At least 1 year of
SLE disease-free time
Potential follow-up period (minimum 12 months)
unless patient died before 12 months of follow-up
Potential index date period
Variable follow-up:
• Leaving CPRD
• End of UTS data
• Death







CPRD patient records with 1 SLE diagnosis, either as
a read code in CPRD or an ICD-10 code in HES
n=7163




Confirmation of SLE diagnosis: satisfied 1 of the
diagnostic or medicinal conditions
n=934
OR OR
Confirmed through 2 records
of SLE ( 60 days apart)






Confirmed through repeat diagnosis
or rheumatologist appointment
or referral to a rheumatologist 
n=839
n=3168 excluded
• Did not have a valid index date (n=1796)
• Did not have 12 months of prior UTSa 
medical history before index date and a 
prior diagnosis-free period of 12 months
(n=336)
• Age <18 years (as of index date) (n=63)
• Index date not within the study period
window (n=261)
• Evidence of cutaneous, drug-induced,
or discoid lupus (n=312)
• Index date after patient transferred out of
practice (n=10)
• No definite code of SLE diagnosis (n=390)




The start of the follow-up period was immediately after the index date. The baseline period was from the index
date to 12 months. Patients were followed until the earliest of these three events: end of study period; leaving
the database/date of patient’s last observed visit; or death. aUTS is the date at which the practice data are deemed
of research quality. CPRD: Clinical Practice Research Datalink; HES: Hospital Episode Statistics; ICD-10: International
Classification of Diseases Tenth Revision; UTS: up-to-standard.
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pre-specified list of clinical manifestations commonly
associated with SLE, as outlined in the algorithm) and
medications (e.g. oral CSs 60 mg/day as severe) [30]
(Supplementary Table S3 and Fig. S1, available at
Rheumatology Advances in Practice online) and has
recently been validated for classifying patients in admin-
istrative datasets [31].
SLE disease severity was defined as mild, moderate
or severe. The assigned disease severity was the high-
est severity experienced by a patient during a 1-year
baseline period (12 months after index). SLE was cate-
gorized as severe if treatment included CYC or an oral
CS (prednisone equivalent) prescription of 60 mg/day
or diagnosis of a severe clinical manifestation (e.g. end-
stage renal disease or arterial/venous thrombosis). A
moderate SLE category was assigned if treatment did
not include CYC or oral CSs 60 mg/day, if there was
presence of a diagnosis of a moderate clinical manifes-
tation (e.g. nephritis or haemolytic anaemia) or if treat-
ment included an oral CS prescription of 7.5 to
<60 mg/day or use of an immunosuppressive agent
(excluding CYC). When patients did not meet criteria
for moderate or severe disease, they were assigned as
mild SLE.
SLE flares were defined using an algorithm adapted
from Garris et al. [30] and based on the Lupus
Foundation second international Lupus Flare Conference
categorization [9], consensus of expert clinical opinion,
and additional criteria including inpatient stays and
accident and emergency (A&E) visits supported by a
qualifying SLE diagnosis or SLE-related condition
(Supplementary Table S3, available at Rheumatology
Advances in Practice online).
SLE flare severity (mild, moderate or severe) was
assessed by a change in treatment or initiation of a new
or higher dose of treatment above a patient’s regular
treatment. Severe flares were identified by: (1) initiation
of a prescription of CYC or oral CSs >40 mg/day or
prednisone-equivalent dose; (2) inpatient admission with
a primary diagnosis for SLE; or (3) inpatient admission
with a primary diagnosis for an SLE-related severe clini-
cal manifestation (Supplementary Table S3, available at
Rheumatology Advances in Practice online). Moderate
flares were identified by: (1) initiation of a prescription of
oral CSs >7.5 to 40 mg/day prednisone-equivalent
dose or immunosuppressive agent (excluding CYC); (2)
an A&E admission with a primary SLE diagnosis but no
inpatient admission; or (3) an A&E admission with
primary or secondary diagnosis for an SLE-related
moderate clinical manifestation. Mild flare included
HCQ or another antimalarial; or oral CS (7.5 mg/day
prednisone-equivalent dose); or non-immunosuppressive
therapy (NSAIDs or androgens).
Measurements and outcomes
Demographics and baseline SLE-related clinical mani-
festations during the 12-month baseline period were
summarized (Fig. 1A). SLE-related clinical manifestations
were identified from a pre-specified list of conditions
used for characterization of disease severity and activity
(Supplementary Table S3, available at Rheumatology
Advances in Practice online); for each condition, the pro-
portion of patients with a record after the index date
was calculated.
SLE treatment patterns, at any time during follow-up,
were summarized for the following medications: oral
CSs (prednisone equivalent); immunosuppressive ther-
apy (AZA, SCA, MTX or MMF); and HCQ or other anti-
malarial (chloroquine phosphate or HCQ sulphate).
Biologics are not captured in the CPRD database
because they are administered in a specialist setting;
hence, they are not included as a treatment category.
We report the type of SLE medication for the total
follow-up period by year, and the mean and median
time to initial and subsequent treatment. We also
assessed, in those patients whose first prescription was
oral prednisone, either an increase in daily dose by
0.5 mg/kg/day or a doubling of daily dose. An increase
in daily dose was defined by a new prescription of the
same product started within 30 days of the end of the
previous one with an increased dosage.
Statistical methods
Data were summarized using descriptive statistics, strat-
ified by disease severity. Annualized flare rates were cal-
culated for the total follow-up period and for each year
of follow-up. We report subsequent flare rates by base-
line disease severity (mild, moderate or severe).
Person-time denominators were used to account for
the varying durations of individual patient follow-up. The
exposure time for each prescribed treatment was
assessed between the treatment start date and the first
of the following events: end of study period; date of
patient’s last observed visit leaving the database; death;
or medicinal management change (a switch from one
treatment to another, an increase in dosage, an addition
of another treatment or a discontinuation).
Kaplan–Meier curves were used to estimate the time
to flare and hazard of flares by disease severity and the
presence of clinical manifestations. We used Gray’s test
for equality of cumulative incidence functions [32].
Statistical analysis was performed using SAS 9.4 (SAS
Institute, Cary, NC, USA).
Results
Study population
From the CPRD database, 7149 patients with an SLE
Read code relating to a primary care consultation
between 1 January 2005 and 31 December 2017 were
identified. An additional 14 with an SLE ICD-10 code
were identified in HES, yielding a total of 7163. Of the
patients identified in the CPRD database, 4214 were
linked to HES, of which 802 patients who had
12 months of prior (baseline) data and 12 months of
follow-up where included in this analysis (Fig. 1B).
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Patient characteristics and clinical manifestations in
the 12-month baseline period are shown in Table 1. The
mean (S.D.) age at index was 48.4 (15.3) years, and
88.4% (n¼ 709) were female. The study population was
classified as: mild disease, 46.0% (n¼ 369); moderate
disease, 43.0% (n¼345); and severe disease, 11.0%
(n¼88) (Table 1).
During the baseline period, 70 patients (8.7%) had a
severe clinical manifestation, and 52 (6.5%) had a mod-
erate clinical manifestation (Table 1). Clinical manifesta-
tions were identified in the renal (7.2%), cerebrovascular
(4.7%), hepatic and gastrointestinal (3.6%), and neuro-
logical (1.0%) organ systems. The most common clinical
manifestations in the study cohort were renal failure
(n¼28, 3.5%), gastrointestinal bleeding and ulcer
(n¼27, 3.4%), stroke/transient ischaemic attack (n¼14,
1.7%), and vasculitis and aortitis (n¼14, 1.7%).
The mean (S.D.) follow-up duration was 5.2 (3.0) years.
During the follow-up period, 43 patients (5.4%) died, of
whom 11 (25.6%) had mild, 18 (41.9%) had moderate,
and 14 (32.5%) had severe SLE.
Medicinal management
The majority of SLE patients (86.3%) were prescribed
SLE medication, with a higher proportion in SLE patients
having severe disease (90.9%) compared with those
who had mild disease (75%) (Table 1). The mean (S.D.)
TABLE 1 Baseline characteristics and comorbidities and treatment during follow-up by severity of disease (Clinical










Proportion female, n (%) 709 (88.4) 326 (88.4) 311 (90.1) 72 (81.8)
Age at index, mean (S.D.), years 48.4 (15.3) 47.1 (14.4) 48.2 (15.7) 53.9 (16.0)
Age group, n (%)
18–44 years 348 (43.4) 169 (45.8) 152 (44.1) 27 (30.7)
45–64 years 321 (40.0) 149 (40.4) 134 (38.8) 38 (43.2)
65 years 133 (16.6) 51 (13.8) 59 (17.0) 23 (26.1)
Follow-up, years
Mean (S.D.) 5.2 (3.0) 5.0 (3.0) 5.6 (3.0) 4.7 (2.8)
Median (25th–75th percentile) 4.9 (2.7–7.3) 4.7 (2.5–7.2) 5.4 (3.1–7.5) 4.3 (2.4–6.5)
Specific clinical manifestationsa,b, n (%)
Cerebrovascular 38 (4.7) 0c 15 (4.3) 23 (26.1)
Moderate condition 19 (2.4) 0c 15 (4.3) 4 (4.5)
Severe condition 19 (2.4) 0c 0c 19 (21.6)
Hepatic and gastrointestinal 29 (3.6) 0c 1 (0.3) 28 (31.8)
Neurological 8 (1.0) 0c 4 (1.2) 4 (4.5)
Renal 58 (7.2) 0c 15 (4.3) 43 (48.9)
Moderate condition 27 (3.4) 0c 15 (4.3) 12 (13.6)
Severe condition 31 (3.9) 0c 0c 31 (35.2)
Musculoskeletal 0c 0c 0c 0c
Ocular 0c 0c 0c 0c
Other 0c 0c 0c 0c
Overall clinical manifestations, n (%)
Any severe comorbidity 70 (8.7) 0c 0c 70 (79.5)
Any moderate comorbidity 52 (6.5) 0c 35 (10.1) 17 (19.3)
Treatment during follow-up, n (%)
No treatmentd 110 (13.7) 94 (25.0) 8 (2.3) 8 (9.1)
Oral CSs 416 (51.9) 78 (21.1) 269 (78.0) 69 (78.4)
Immunosuppressants (excluding CYC) 203 (25.3) 0e 175 (50.7) 28 (31.8)
Antimalarials 557 (69.5) 254 (68.8) 251 (72.8) 52 (59.1)
Biologicsf – – – –
aClinical manifestations were those included in the disease severity algorithm and were identified during the 12-month
baseline period after the index date (included clinical manifestations are outlined in Supplementary Table S3, available at
Rheumatology Advances in Practice online). bCategories not mutually exclusive. cMild disease activity reflects clinically sta-
ble disease with no life-threatening organ involvement (i.e. no moderate or severe SLE-related comorbidities). dNo treat-
ment in this context means that there is no record of prescriptions for oral CSs, immunosuppressants or antimalarials;
however, patients might have been treated with other medications. eBy definition, no immunosuppressant use indicates
mild disease. fBiologics use is not captured in the Clinical Practice Research Datalink because they are administered in a
specialist care setting.
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time to initiating any treatment (antimalarials, oral CS or
immunosuppressants) after SLE diagnosis was 177
(385.3) days, and the median [interquartile range (IQR)]
time to treatment was 35.5 (7–136.5) days. For antima-
larials, oral CSs and immunosuppressants, the mean
(S.D.) time was 133.7 (292.0), 241.4 (488.4) and
197.2 (407.7) days, respectively. Median time (IQR) was
34.0 (7–119), 41.5 (10–186), and 25 (4–124) days,
respectively (Table 2; Supplementary Fig. S2, available
at Rheumatology Advances in Practice online). A higher
proportion of patients who were first prescribed immu-
nosuppressants (78.0%) and oral CS (65.0%) subse-
quently went on to initiate another drug, compared with
those first prescribed antimalarials (41.1%) (Table 2).
The proportion of patients prescribed oral CSs and
immunosuppressants increased (from 51.9 to 57.5%
and from 25.3 to 31.3%, respectively) across years 1–6
of follow-up, whereas the use of antimalarials remained
stable over time (Table 3).
Of patients first prescribed oral CS (n¼ 254) at any
time since the index date, 27 patients (10.6%) had an
increase in daily dose of 0.5 mg/kg/day or a doubling
of daily dose during the follow-up period. Furthermore,
44 (17.3%) and 97 patients (38.2%) were also pre-
scribed NSAIDs and antimalarials, respectively, within
30 days of the end of the previous oral CS prescription.
Frequency and severity of flares
Almost all patients (n¼ 750, 93.5%) experienced at
least one flare following the index date to end of
follow-up (Table 4; Supplementary Fig. S3, available at
Rheumatology Advances in Practice online). The mean
(S.D.) annualized flare rate over the entire follow-up
period was 3.3 (2.2). The annualized flare rates (S.D.)
were 0.2 (0.6) for severe flares, 0.6 (1.3) for moderate
flares, and 2.4 (2.1) for mild flares. The mean annual
flare rates by severity during the first year after SLE
TABLE 2 Time to first prescription and follow-up treatment by type of first prescription (Clinical Practice Research
Datalink 2005–2017)
Parameter Oral CSs Immunosuppressantsb Antimalarials
First prescriptiona, n (%)
Patients 254 (31.7) 41 (5.1) 397 (49.5)
Time to first prescription
Mean (S.D.), days 241.4 (488.4) 197.2 (407.7) 133.7 (292.0)
Median (IQR), days 41.5 (10–186) 25.0 (4–124) 34.0 (7–119)
Subsequent treatmenta, n (%)
Oral CSs only 89 (35.0) 0 0
Immunosuppressants only 0 9 (22.0) 0
Antimalarials only 0 0 234 (58.9)
Oral CSs and immunosuppressants 24 (9.4) 13 (31.7) 0
Oral CSs and antimalarials 80 (31.5) 0 86 (21.7)
Immunosuppressants and antimalarials 0 3 (7.3) 30 (7.6)
Oral CSs, immunosuppressants and antimalarials 61 (24.0) 16 (39.0) 47 (11.8)
aTreatment categories not mutually exclusive; a patient could have monotherapy or a combination of prescriptions as the
first or subsequent prescription. bExcluding CYC. IQR: interquartile range.




Years of follow-up since index date
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6
Overall, n 802 802 675 569 472 385 294
Proportion of patients on treatment, n (%)b
No treatmentc 110 (13.7) 110 (13.7) 93 (13.8) 78 (13.7) 64 (13.6) 49 (12.7) 34 (11.6)
Oral CS 416 (51.9) 416 (51.9) 361 (53.5) 307 (53.9) 257 (54.5) 215 (55.8) 169 (57.5)
Immunosuppressantsd 203 (25.3) 203 (25.3) 180 (26.7) 155 (27.2) 135 (28.6) 118 (30.7) 92 (31.3)
Antimalarials 557 (69.5) 557 (69.5) 471 (69.8) 397 (69.8) 326 (69.1) 271 (70.4) 206 (70.1)
aMean follow-up of cohort ¼ 5.2 years. bTreatment groups not mutually exclusive. cNo treatment in this context means that
there is no record of prescriptions for oral CSs, immunosuppressants or antimalarials; however, patients might have been
treated with other medications. dExcluding CYC.
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diagnosis are shown in Table 4. There was a trend for
the annual rate to be slightly higher in year 1 than in
subsequent years. For patients whose first flare was
mild, subsequent flares were more likely to be mild
flares; annualized flare rate (S.D.) 2.4 (2.1) compared with
moderate flares 0.6 (1.3) or severe flares 0.2 (0.6).
Likewise, when patients experienced an initial moderate
or severe flare, the subsequent annualized flares rates
were highest for moderate and severe flares,
respectively.
The median time to a flare of any type was 63 days
(95% CI: 57, 71). Persons with moderate and severe
SLE had the shortest median time to first flare (52 days;
95% CI: 43, 65 and 61 days; 95% CI: 55, 74, respec-
tively), followed by mild SLE (84 days; 95% CI: 64, 107;
P<0.001; Fig. 2A). Patients with an SLE-related clinical
manifestation had a lower median time to first flare
(53.5 days; 95% CI: 41, 70) compared with those without
a condition (67 days; 95% CI: 57, 78; P< 0.001;
Fig. 2B). Age and sex were not associated with the
median time to first flare (P¼0.478 and P¼ 0.745,
respectively).
Discussion
In this longitudinal, observational cohort study charac-
terizing newly diagnosed patients with SLE in the UK,
the mean annualized flare rate identified using medical
and administrative data over the whole follow-up period
was 3.3 for all patients, with a median time to first flare
that is significantly shorter for patients with moderate
and severe disease: 52 and 61 days, respectively. We
identified that moderate and severe SLE-related comor-
bidity affects multiple organ systems. We also deter-
mined that the presence of an SLE-related comorbidity
shortened the time to first flare. Our findings suggest
that it takes an average of slightly <6 months to receive
treatment with antimalarial agents, oral CSs or immuno-
suppressive agents after an SLE diagnosis, and a con-
sistently high proportion of patients (between 52% and
58%) continue to receive oral CSs as part of their
treatment regimen over 6 years. These findings highlight
potential delays in initiating treatment in newly
diagnosed patients with SLE, in addition to high and
sustained use of oral CSs over time. The burden of SLE
flares was highest among patients with moderate and
severe SLE and in patients with comorbidities, both of
whom experience a shorter time to flare, at which time a
large proportion of newly diagnosed patients might not
have initiated treatment.
Medical management of SLE in the cohort included
antimalarial agents, oral CSs and immunosuppressive
agents and is generally in line with UK and European
(EULAR) SLE treatment guidelines [2, 12]. The goals of
treatment are to improve long-term patient outcomes
and health-related quality of life; therefore, treatment
regimens should be selected with the aim of remission
of disease symptoms and signs, prevention of damage
accrual, prevention of flares and minimization of drug
side effects [12]. EULAR guidelines recommend antima-
larials for all SLE patients. Our findings show that 70%
of patients were prescribed antimalarials, with a mean
duration of 134 days to initiate treatment after diagnosis,
which is the shortest time to initiation for any of the
treatments included in this analysis. EULAR guidelines
also recommend the use of oral CSs for rapid symptom
relief, with a medium- to long-term aim of minimizing the
daily dose or to discontinue them owing to drug side
effects [12]. Our study demonstrated that the use of oral
CSs was high (52–58%) and remained consistently high
during 6 years of follow-up. In addition, 10% of patients
had an increase or doubling in the daily dose of an
oral CS.
The use of medical records and claims-based
algorithms to categorize SLE disease severity and flares
has increased the usability of observational data to sup-
port our understanding of the real-world burden of SLE.
In the present study, 54% of patients were categorized
as having moderate or severe SLE at baseline, and
11.0% were categorized has having severe disease. A
previous observational study from the USA, which also
used a claims-based algorithm, identified a higher pro-
portion of patients with moderate and severe disease
TABLE 4 Annual flare rates by severity of first flare over follow-up period (Clinical Practice Research Datalink 2005–2017)
Parameter Any flare Mild flares Moderate flares Severe flares
First SLE flare, n (%) 750 549 (73.2) 116 (15.5) 85 (11.3)
Follow-up years, annual flare rate by severity of first flare; annual flare rate (S.D.)
Total follow-up perioda (n¼802) 3.3 (2.2) 2.4 (2.1) 0.6 (1.3) 0.2 (0.6)
Year 1 (n¼802) 3.5 (2.5) 2.6 (2.5) 0.7 (1.5) 0.2 (0.6)
Year 2 (n¼675) 3.1 (2.5) 2.4 (2.4) 0.6 (1.5) 0.1 (0.4)
Year 3 (n¼569) 3.2 (2.6) 2.4 (2.5) 0.7 (1.7) 0.1 (0.5)
Year 4 (n¼472) 3.1 (2.6) 2.3 (2.5) 0.7 (1.6) 0.1 (0.5)
Year 5 (n¼385) 3.0 (2.6) 2.2 (2.4) 0.7 (1.7) 0.1 (0.5)
Year 6 (n¼294) 3.1 (2.6) 2.3 (2.4) 0.7 (1.6) 0.1 (0.6)
aMean follow-up of cohort ¼ 5.2 years.
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(moderate, 52.1% and severe, 21.5%) [30]. The lower
proportion of severe disease identified in the present
study might be attributable, in part, to the unavailability
of data on biologic agents within the CPRD and HES
data. Biologics, such as belimumab or off-label rituxi-
mab, are recommended by guidelines for use only in
patients with more severe disease and inadequate
control or refractory to other agents [12]. Claims-based
studies, which use medical records and administrative
data when available, might have utility in categorizing
SLE disease severity when clinical characterization is
not available [31]. The algorithms used in the present
study involve classification by prescription data and clin-
ical manifestations with linkage to hospital and mortality
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Dashed lines in the main plot show the 25th percentile. Dashed lines in the inset show the 50th percentile (median).
Corresponding values (days) are given. (A) This analysis was conducted on the cohort of patients with any length of
follow-up and not restricted to those with 12 months of follow-up (n¼934). (B) The presence of a clinical manifesta-
tion was based on the cohort with 12 months of follow-up (n¼802). Clinical manifestations were adjusted for age,
sex, SLE severity and comorbidities.
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records, which is an enhancement of previous classifica-
tion systems that use only prescription data [22]. Our
study identified flares in 93.5% of the cohort and an
overall mean annual flare rate per patient of 3.3. This is
comparable to the observational study conducted in the
USA, in whic 95.7% of the cohort experienced flares,
and the mean number of flares per patient over 2 years
was 6.7 [30].
The use of individual patient-level data extracted from
a large nationwide general practice records database
and linked to hospital and mortality records is one of
the strengths of this study. Our study cohort is repre-
sentative of the UK general population, which makes
our findings generalizable to patients in the UK with SLE
treated in primary care. The ability to follow patients
over 6 years improves real-world understanding of
longitudinal trends in SLE disease characteristics and
treatment. The CPRD has been used for a number of
SLE-related studies, mostly to assess the incidence of
SLE in the UK [17–28]. The most recent CPRD study
used a case-identification algorithm; however, no link-
age to HES or categorization of disease activity was
made, and categorization of disease severity was done
using prescription records only [22].
The limitations of our study are common to retrospec-
tive observational studies using routinely collected elec-
tronic health record data. First, CPRD GOLD linkage
data are available for only 50% of contributing CPRD
GOLD practices in the UK. In addition, these data may
include missing data and potential biases, such as mis-
classification biases, or inconsistencies in coding within
and between practices and over time. To reduce poten-
tial misclassification in our study, we required linkage
with HES and 12 months of follow-up and, in addition,
we required confirmation of SLE diagnosis through re-
peat diagnosis of SLE (in CPRD or HES), through a
rheumatologist appointment or referral, or through SLE
medication use. This might represent an underestimation
of the true number of SLE cases and an overestimation
of patients with more severe disease. However, only
1.8% (n¼ 126) of patients were excluded owing to a
lack of additional verifying information. This indicates
that the potential bias created by requiring confirmation
of SLE diagnosis is small. Second, drugs prescribed in
the specialist setting, such as biologics, are not avail-
able routinely in the CPRD and are therefore not in-
cluded in this study.
Furthermore, the use of electronic health records to
assign severity of disease and flares can be challenging,
because SLE is a clinically complex disease, and dis-
ease severity and activity measures, such as the
SLEDAI-2K, are not captured routinely in real-world
databases or administrative and claims data [22, 29,
33]. However, we adapted algorithms developed for a
study from the USA that used information about pre-
scriptions and clinical manifestations to determine both
disease severity and flare severity. The algorithms were
developed from existing validated tools and clinical
opinion [30] and have recently undergone validation
against the SLEDAI-2K and been shown to have accept-
able performance for classification of SLE severity [31].
Although further validation of these algorithms, which
serve as a proxy for SLE disease and flare severity, is
warranted, the use of real-world evidence to understand
SLE would be vastly improved if validated measures of
disease severity and flares were routinely captured in
electronic health record and claims data for use in future
observational research.
This study provides a detailed picture of SLE disease
severity and flares over time in patients in the UK,
together with an overview of current medical manage-
ment patterns and the types of comorbidities present.
Our findings suggest potential delays in SLE treatment
initiation in the UK. Early treatment might delay or
reduce the severity of the first SLE flare after diagnosis
and might translate to slower disease progression, lower
organ damage accrual, better outcomes and improved
health-related quality of life.
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